Retatrutide

Overview

Retatrutide is an investigational research peptide that acts as a novel triple agonist targeting the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. It is being studied for its potential impact on metabolic pathways and body weight regulation in preclinical models such as lab rodents.

Benefits

In controlled laboratory research, Retatrutide has shown the potential to support significant weight reduction and improved glucose regulation in test subjects like rodents. Early studies indicate that multi-receptor agonists may demonstrate enhanced effects on weight and metabolic markers compared to single or dual agonists.

Source: Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. New England Journal of Medicine, 2023. Link

Side Effects

In preclinical and clinical settings, test subjects administered Retatrutide have demonstrated side effects similar to other GLP-1 receptor agonists. These may include gastrointestinal disturbances such as reduced food intake, nausea, and mild discomfort. Other reported effects in research models include mild elevations in heart rate and possible injection site reactions.

Source: Jastreboff AM, et al. NEJM, 2023. Link

Dosage and Administration

In laboratory studies, Retatrutide is administered via subcutaneous injection. Typical research protocols have investigated doses ranging from 1 mg to 12 mg per week, depending on the desired study outcome and the species of the research subject. Administration is commonly performed once per week to monitor metabolic markers and weight changes in test animals.

Note: All handling and dosing must comply with institutional research guidelines. Retatrutide is not approved for human consumption.

Summary

Retatrutide is a novel multi-receptor agonist peptide researched for its promising effects on metabolic regulation in test animals. Studies indicate it may provide significant weight reduction and improved glucose control, though side effects such as mild gastrointestinal issues have been observed. It is typically administered by subcutaneous injection once weekly, with dosage depending on the research protocol and test species. Retatrutide remains strictly for laboratory research use only.